van der Ree Martijn H, Blanck Oliver, Limpens Jacqueline, Lee Charlie H, Balgobind Brian V, Dieleman Edith M T, Wilde Arthur A M, Zei Paul C, de Groot Joris R, Slotman Ben J, Cuculich Phillip S, Robinson Clifford G, Postema Pieter G
Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam UMC, University of Amsterdam, Cardiovascular Sciences, Amsterdam, The Netherlands.
Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Kiel, Germany; Department of Internal Medicine III, Cardiology, Section for Electrophysiology, University Medical Center Schleswig-Holstein, Kiel, Germany.
Heart Rhythm. 2020 Aug;17(8):1381-1392. doi: 10.1016/j.hrthm.2020.03.013. Epub 2020 Mar 20.
Failure of drugs and catheter ablation procedures for the treatment of ventricular arrhythmias is still extremely relevant. Recently, stereotactic body radiotherapy has been introduced to treat therapy refractory patients. In this systematic review (International Prospective Register of Systematic Reviews, CRD42019133212), we aimed to summarize electrophysiological and histopathological effects of radioablation in animals, patients, and extracted and perfused hearts. A systematic search was performed in OVID MEDLINE, OVID Embase, the Cochrane Central Register of Controlled Trials, Web of Science, Google Scholar, ClinicalTrials.gov, and World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) from inception to September 2019. Identified records were independently screened for eligibility by 2 reviewers. Risk of bias and methodological quality were assessed using the SYRCLE, ROBINS-I, or Murad tool and tailored to the different study designs. We included 13 preclinical and 10 clinical publications. Large heterogeneity in study designs prompted a narrative synthesis approach. Baseline, (pre-)procedural details, outcome, target tissue analyses, and safety data were extracted and summarized. In animal studies evaluating electrophysiological parameters, radioablation induced a reduction in voltage/potential amplitude or bidirectional block in target areas in 93.2% of animals. Atrioventricular block (first to third degree) was induced in 78.3% of animals, and in studies evaluating ventricular arrhythmia inducibility, 75% reduction was achieved. In patients, predominantly ventricular tachycardias were targeted with >85% reduction in arrhythmia episodes during follow-up with an encouraging short-term safety profile. Preclinical and clinical evidence on the efficacy and safety of radioablation is limited in both quantity and quality. The results of radioablation for therapy refractory patients with ventricular tachycardia are promising, but further research is needed.
药物及导管消融术治疗室性心律失常失败的情况仍然极为常见。最近,立体定向体部放射治疗已被用于治疗难治性患者。在本系统评价(国际系统评价前瞻性注册库,CRD42019133212)中,我们旨在总结放射消融在动物、患者以及摘取并灌注的心脏中的电生理和组织病理学效应。从建库至2019年9月,我们在OVID MEDLINE、OVID Embase、Cochrane对照试验中心注册库、科学网、谷歌学术、ClinicalTrials.gov以及世界卫生组织国际临床试验注册平台(WHO ICTRP)进行了系统检索。由两名评审员独立筛选确定的记录是否符合纳入标准。使用SYRCLE、ROBINS-I或Murad工具评估偏倚风险和方法学质量,并根据不同的研究设计进行调整。我们纳入了13篇临床前和10篇临床出版物。研究设计存在较大异质性,因此采用了叙述性综合分析方法。提取并总结了基线、(术前)手术细节、结果、靶组织分析和安全性数据。在评估电生理参数的动物研究中,93.2%的动物经放射消融后靶区域电压/电位幅度降低或出现双向阻滞。78.3%的动物出现房室阻滞(一度至三度),在评估室性心律失常诱发性的研究中,室性心律失常诱发率降低了75%。在患者中,主要针对室性心动过速进行治疗,随访期间心律失常发作次数减少>85%,短期安全性令人鼓舞。关于放射消融疗效和安全性的临床前和临床证据在数量和质量上均有限。放射消融治疗难治性室性心动过速患者的结果很有前景,但仍需进一步研究。